Evaluation of existence and transmission of extended spectrum beta lactamase producing bacteria from post-delivery women to neonates at Bugando Medical Center, Mwanza-Tanzania

Edwin Nelson1†, Juma Kayega1†, Jeremiah Seni1*, Martha F Mushi1, Benson R Kidunya2, Adolfine Hokororo3, Antke Zuechner3, Albert Kihunrwa4 and Stephen E Mshana1

Abstract
Background: Extended spectrum beta-lactamase producing bacteria (ESBL) are common causes of neonatal sepsis worldwide. Neonatal sepsis due to ESBL is associated with increased morbidity and mortality at Bugando Medical Centre (BMC). Due to limited information on the sources of these ESBL strains at BMC, this study was conducted to evaluate the existence, magnitude and transmission of ESBL from post-delivery women to neonates at BMC, Mwanza-Tanzania.

Results: A cross-sectional study was conducted at obstetrics and neonatal wards from May to July 2013, involving post-delivery women and their neonates. Rectal swabs were collected and processed to identify the ESBL strains and their antimicrobial susceptibility patterns. Patients’ data were obtained using a standardized data collection tool. We enrolled 113 women and 126 neonates with mean age of 26.5 ± 5.5 years and median gestation age (IQR) of 39 [35–40] weeks respectively. The prevalence of ESBL carriage among women and neonates were 15% (17/113) and 25.4% (32/126) respectively. The acquisition of ESBL isolates among neonates on day 1, day 3 and day 7 were 60.0% (21/35), 25.7% (9/35) and 14.3% (5/35) respectively. There was no phenotypic similarity between ESBL strains from women and their respective neonates, suggesting other sources of transmission. Neonates given antibiotics were more likely to carry ESBL than those not given [100% (32/32) versus 86% (81/94), p = 0.018].

Conclusion: The carriage rate of ESBL strains among post-delivery women and neonates at BMC is high. Our findings suggest that neonates acquire these strains from sources other than post-delivery women and more than half acquire them on the first day of life. More studies are recommended to further explore the sources of ESBL strains among neonates.

Keywords: ESBL, Post-delivery women, Neonates, Tanzania

Background
The escalating burden of multidrug resistant (MDR) gram negative bacteria of the family Enterobacteriaceae is currently one of the most challenging situations both in developed and developing countries [1-4]. The exposure of these bacteria notably, Escherichia coli and Klebsiella pneumoniae to antibiotics especially in the hospital environment has induced dynamic and continuous mutation leading to production extended spectrum beta lactamase (ESBL) which confer resistance to first, second, third and fourth generation cephalosporins as well as aztreonam [5-7]. These ESBL strains in turn have spread not only in the hospital environment but also to the community settings with significant regional variations [4,6,8,9]. Although shown in few studies, gastrointestinal carriage of ESBL strains can be a predictor of subsequent infection [10-12]. The prevalence of ESBL carriage has been shown
to range from 3.2% to 67.9% [12-16]. Furthermore, pregnant women colonized by ESBL in the gastrointestinal tract have a potential to subsequently transmit these strains to their neonates (during and after delivery), to other hospitalized patients and to health workers [17,18]. Few studies have addressed the magnitude of ESBL associated infections with undue complications and deaths in Tanzania [3,9,19-21] however information showing the ESBL carriage among post-delivery women and their neonates remain to be explored. Thus, this study aimed at evaluating the existence, magnitude and transmission of ESBL strains from post-delivery women to their neonates during or after delivery so as to specifically guide infection prevention and control at Bugando Medical Center (BMC) where ESBL associated infections have been shown to be an independent predictor of deaths among neonates [3].

Methods

Study design and sampling procedures

This was a cross sectional hospital based study conducted from May to July 2013 in the obstetrics wards, neonatal ICU and neonatal wards at BMC. Post-delivery women who delivered at BMC within 24 hours and who consented to participate in the study were serially recruited and their respective neonates. The sample size of 113 post-delivery women was estimated using Kish Leslie (1965) formula and using a previous prevalence of 8% [14].

Data and clinical sample collection

Every post-delivery woman was informed about details regarding the aims of the study. A standardized data collection tool and patients’ files were used to collect demographic and clinical data among consented women and their respective neonates. Then, after a thorough explanation, using sterile cotton swab in Amies transport medium (Biolab, HUNGARY) rectal swabs were collected from women within 24 hours after delivery. To assess acquisition of ESBL strains in neonates, the rectal swabs were collected on day 1, day 3 and day 7 post-delivery. Rectal swab specimens were delivered to the Laboratory within two hours after collection.

Laboratory procedures

The rectal swab samples were plated onto MacConkey agar (OXOID, Basingstoke, UK) supplemented with cefotaxime 2 mg/L for preliminary screening of ESBL bacterial isolates and then plates were incubated at 35-37°C for 18–24 hours. All gram negative bacteria were identified using phenotypic characteristics such as lactose fermentation reaction on Mac Conkey agar, Urease, Citrate, Sulphur indole motility (SIM) and Triple sugar iron (TSI) tests as previously described [22].

Susceptibility testing was done using disc diffusion method based on the Clinical Laboratory Standard Institute (CLSI) guideline [23]. The antibiotic discs tested were ampicillin (10 μg), amoxicillin/clavulanate (20/10 μg), ciprofloxacin (5 μg), tetracycline (30 μg), gentamicin (10 μg), sulfamethoxazole/trimethoprim (1.25/23.75 μg), ceftriaxone (30 μg), ceftazidime (30 μg) and imipenem (10 μg) (OXOID, Basingstoke, UK). The phenotypic confirmation of ESBL isolates was done using disc approximation method i.e. ceftazidime (30 μg) and cefotaxime (30 μg) discs were placed equidistant from the amoxicillin/clavulanate (20/10 μg) disc, followed by overnight incubation at 37°C for 18–24 hrs. Enhanced zone of inhibition towards amoxicillin/clavulanate disc was considered as positive result for ESBL production whereas interpretation of susceptibility patterns on other antimicrobial disks was done using guidelines laid down in the CLSI, which provides break points corresponding to zone of inhibition diameter [9,23].

Quality control

Standard laboratory procedures were strictly adhered to so as to avoid contamination. Escherichia coli ATCC 25922 and Escherichia coli ATCC 35218 were used as negative and positive ESBL controls respectively.

Data management and analysis

The demographic, clinical and laboratory data were entered into Microsoft excel and then exported to the STATA version 11.0 software for analysis according to the objectives of the study. Results were presented into percentages/proportions for categorical variables whereas continuous variables were described as mean (±standard deviation). The difference in distribution of predictor variable was considered significant if p-value was less than 0.05.

Study clearance and ethical consideration

The study was approved by CUHAS/BMC Ethical Review Board, and written informed consent was obtained from every post-delivery woman (who also provided consent for her neonate) before collection of demographic, clinical data and rectal swab specimens.

Results

A total of 113 post-delivery women and 126 neonates with mean age of 26.5 ± 5.5 years and median gestation age [IQR] of 39 [35–40] weeks respectively were recruited. The prevalence of ESBL carriage among post-delivery women and neonates were 15% (17/113) and 25.4% (32/126) respectively. The cumulative number of ESBL bacterial isolates among post-delivery women and neonates were found to be 20 and 35 respectively throughout the study (three post-delivery women and neonates had dual ESBL carriage). The most predominant ESBL isolates among
post-delivery women were *Escherichia coli* (30%, 6/20) followed by *Enterobacter spp* (20%, 4/20) whereas the predominant species in neonates were *Klebsiella pneumoniae* (77.1%, 27/35) followed by *Escherichia coli* (14.3%, 5/35) (Figure 1).

The acquisition of ESBL isolates among neonates on day 1, day 3 and day 7 were 60.0% (21/35), 25.7% (9/35) and 14.3% (5/35) respectively. Furthermore, there was no phenotypic similarity between ESBL strains from post-delivery women and their respective neonates.

There was no statistical significant association between ESBL-carriage among post-delivery women and variables such as age, mode of delivery, history of antibiotic use in the past or current admission, the presence of i/v line, urinary catheter insitu as well as HIV seropositivity. Neonates given antibiotics were more likely to carry ESBL

![Figure 1 The proportion of ESBL bacterial isolates' carriage among post-delivery women and neonates at BMC.](image)

### Table 1 Association between ESBL carriage among post-delivery women with variables

| Variable                                      | Non ESBL carrier, n (%) | ESBL carrier, n (%) | p-value |
|-----------------------------------------------|-------------------------|---------------------|---------|
| **N = 96**                                    |                         | **N = 17**          |         |
| Mean age ± SD<sup>ǂ</sup>                     | 27.1 ± 5.5 years        | 23.4 ± 3.6 years    | 0.084   |
| Mode of delivery                              |                         |                     |         |
| C/S*                                         | 36 (37.5)               | 8 (47.1)            | 0.456   |
| SVD**                                        | 60 (62.5)               | 9 (52.9)            |         |
| Admission in the past 30 days                 |                         |                     |         |
| No                                           | 96 (100)                | 17 (100)            | -       |
| Yes                                          | 0 (0.0)                 | 0 (0.0)             |         |
| Admission in the past 3 months                |                         |                     |         |
| No                                           | 83 (86.5)               | 13 (76.5)           | 0.288   |
| Yes                                          | 13 (13.5)               | 4 (23.5)            |         |
| Previous use of antibiotics in the past 30 days |                         |                     |         |
| No                                           | 67 (69.8)               | 9 (52.9)            | 0.172   |
| Yes                                          | 49 (50.2)               | 8 (47.1)            |         |
| Previous use of antibiotics in the past 3 months |                         |                     |         |
| No                                           | 54 (56.3)               | 7 (41.2)            | 0.250   |
| Yes                                          | 42 (43.7)               | 10 (58.8)           |         |
| Antibiotics use in the current admission      |                         |                     |         |
| No                                           | 57 (59.4)               | 9 (52.9)            | 0.620   |
| Yes                                          | 39 (40.6)               | 8 (47.1)            |         |
| Presence of catheter                         |                         |                     |         |
| No                                           | 59 (61.5)               | 10 (58.8)           | 0.837   |
| Yes                                          | 37 (38.5)               | 7 (41.2)            |         |
| Presence of i/v line                         |                         |                     |         |
| No                                           | 54 (56.3)               | 10 (58.8)           | 0.844   |
| Yes                                          | 42 (43.7)               | 7 (41.2)            |         |
| HIV serostatus                                |                         |                     |         |
| Negative                                     | 84 (87.5)               | 16 (94.1)           | 0.431   |
| Positive                                     | 12 (12.5)               | 1 (5.9)             |         |

*Standard deviation; *Caesarean section; **Spontaneous vaginal delivery.
than those not given [100% (32/32) versus 86% (81/94), p = 0.018]. The mortality rates among neonates carrying ESBL was relatively higher as opposed to non-carriers though the difference was not statistically significant (12.5%, 5/32 versus 9.6%, 9/94 respectively; p-value = 0.638) (Tables 1 & 2).

The ESBL bacterial isolates in this study showed borderline resistance to ciprofloxacin among post-delivery women (55.0%, 11/20) and neonates (34.3%, 13/35). All ESBL strains were sensitive to imipenem (Table 3).

**Discussion**

The prevalence of ESBL carriage among women shown in this study (15%) is relatively close to 10% to 12.7% found in some Asian and African countries [13,15,16] but lower than 3% and 3.2% in Sweden and USA respectively [11,24]. The lower rates in ESBL carriage in developed countries as opposed to developing countries may be attributable to different policies in antimicrobial use and infection control in the respective settings. The present study and a similar one in Madagascar found the rates of ESBL carriage in children to be 15% and 22.1% respectively, with acquisition increasing progressively in the course of hospitalization [25]. This emphasizes the need to protect this vulnerable population of children against the MDR strains in the hospital settings. The predominance of *Escherichia coli* and *Klebsiella pneumonia* producing ESBL strains in this study is also similar to findings in some other studies across the world showing their preponderance in gastrointestinal tract colonization and their evolutionary potential into MDR strains [12,15,25,26].

It is well known that gastrointestinal carriage of ESBL strains among pregnant women can be a potential source of transmitting these resistant strains to their newborns [17,18] but contrary to this, there was no phenotypic similarity between ESBL strains from women and their respective neonates. This suggests that effective control of transmission of ESBL strains at BMC should go beyond mothers and that other possible sources should be further scrutinized so as to curb the growing burden of antimicrobial resistance in Tanzania [3,20] and other countries with similar problem [4,7].

As shown in some other studies [25-29], previous use of antibiotics among neonates has also been shown to be associated with ESBL carriage in the present study. The possible reason of high neonatal ESBL carriage in our setting may be due to antimicrobial selective pressure conferred by the empirical use of ampiclox and cefotaxime. Therefore, as shown from other settings [11], neonatal screening for ESBL strains and adherence to the rational antimicrobial use policy should be an enduring exercise at BMC. Other predictive factors such as older age, prolonged hospitalization, vaginal delivery, low birth weight and prematurity though shown in other studies [14,25,26,30] were not found to be statistically associated with ESBL carriage in the present study.

The MDR nature of the ESBL isolates in the present study is worrisome as these post-delivery women and their neonates may be the potential sources of these

| Variable                        | Non ESBL carrier, n | ESBL carrier, n | p-value |
|---------------------------------|---------------------|-----------------|---------|
| Median gestational (IQR)        | 39 (35–40)          | 39 (35–40)      | 0.710   |
| Median birth weight (kg)        | 2.6 (1.9-3)         | 2.9 (1.7-3.4)   | 0.365   |
| Sex                             |                     |                 |         |
| Female                          | 44 (46.8%)          | 17 (53.1%)      | 0.537   |
| Male                            | 50 (53.2%)          | 15 (46.9%)      |         |
| Mode of Delivery                |                     |                 |         |
| C/S*                            | 35 (37.2%)          | 12 (37.5%)      | 0.979   |
| SVD**                           | 59 (62.8%)          | 20 (62.5%)      |         |
| Ward                            |                     |                 |         |
| NICU*                           | 19 (20.2%)          | 8 (25.0%)       | 0.569   |
| C2NU**                          | 75 (79.8%)          | 24 (75.0%)      |         |
| Antibiotic Use                  |                     |                 |         |
| No                              | 13 (13.8%)          | 0 (0.0%)        | 0.018   |
| Yes                             | 81 (86.2%)          | 32 (100.0%)     |         |
| Outcome                         |                     |                 |         |
| Discharged                      | 85 (90.4%)          | 28 (87.5%)      | 0.638   |
| Died                            | 9 (9.6%)            | 4 (12.5%)       |         |

Interquantile range; *Caesarian section; **Spontaneous vagina delivery; *Neonatal intensive care unit; **Ward C2 neonatal unit.

### Table 3 Antimicrobial resistance patterns among ESBL isolates from post-delivery women and neonates

| Antibiotic agents | Post-delivery women, n (%) | Neonates, n (%) |
|-------------------|----------------------------|-----------------|
|                   | N = 20                     | N = 35          |
| Co-trimoxazole    | 20 (100.0)                 | 25 (71.4)       |
| Tetracycline      | 14 (70.0)                  | 17 (48.6)       |
| Gentamicin        | 15 (75.0)                  | 32 (91.4)       |
| Ciprofloxacin     | 11 (55.0)                  | 12 (34.3)       |
| Imipenem          | 0 (0.0)                    | 0 (0.0)         |
strains in the hospital environment, and should of necessity be among the target groups in infection prevention and control activities at BMC. The present study has shown excellent activity of carbapenems and borderline activity of ciprofloxacin against ESBL strains, the findings which are similar to other studies [8,25].

Conclusion
The carriage rates of ESBL strains among neonates and their mothers at BMC are high. Our findings suggest that neonates acquire these strains from sources other than post-delivery women and more than half acquire them on the first day of life. These two groups should be among the target groups for ESBL screening at BMC so as to prevent ESBL spread in the hospital environment. In the light of these findings, more studies are recommended to further explore the sources of the ESBL strains among neonates.

Competing interests
Authors declare that they have no competing interests.

Authors’ contributions
Conceived, designed and executed the study: EN, JK, JS, MFM, BRK and SEM; Laboratory analysis of samples: EN, JK, JS, MFM and SEM; Data collection and analysis: EN, JK, JS and BRK. Wrote the initial draft of the manuscript: EN, JS and JK which was critically revised by all authors. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to sincerely thank all post-delivery women and their neonates for participating in this study. All staffs in the Department of Obstetrics & Gynaecology, Paediatrics & Child Health as well as Microbiology & Immunology of CUHAS and BMC for their excellent technical support. This work was internally funded by CUHAS to SEM and reagents from SACIDS to SEM.

Author details
1Department of Microbiology/Immunology, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania. 2Department of Biochemistry and Molecular Biology, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania. 3Department of Pediatrics and Child Health, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania. 4Department of Obstetrics and Gynaecology, Catholic University of Health and Allied Sciences, P.O. Box 1446, Mwanza, Tanzania.

Received: 6 January 2014 Accepted: 28 April 2014 Published: 3 May 2014

References
1. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bantlett JS. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin Infect Dis 2006, 42(5):657–668.
2. Schwaber MJ, Carmeli Y: Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007, 60(5):913–920.
3. Kayange N, Kamugisha E, Mwindimba DL, Jeremiah S, Mshana SE: Predictors of positive blood culture and deaths among neonates with suspected neonatal sepsis in a tertiary hospital, Mwanza-Tanzania. BMC Pediatr 2010, 10:39.
4. Seni J, Najuka CF, Kateete DP, Malobore P, Joboba ML, Kajumbula H, Kapesa A, Bwanga F: Antimicrobial resistance in hospitalized surgical patients: a silently emerging public health concern in Uganda. BMC Res Notes 2013, 6:298.
5. Bradford PA. Extended-spectrum beta-lactamas in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001, 14(4):933–951. table of contents.
6. Samaha-Kfoury JN, Araj GF: Recent developments in beta lactamas and extended spectrum beta lactamas. BMJ 2003, 327(7425):1229–1233.
7. Woetrher PL, Angebault C, Jacquier H, Hugerde HC, Janssens AC, Sayadi S, El Mnaï A, Armand-Lefevre L, Ruppe E, Barbier F, Rackine L, Page AL, de Rekeineire N, Andremont A: Massive increase, spread, and exchange of extended spectrum beta-lactamase-encoding genes among intestinal Enterobacteriaceae in hospitalized children with severe acute malnutrition in Niger. Clin Infect Dis 2011, 53(7):677–685.
8. Nijenson S, Florijn A, Bonten MJ, Schmitz FJ, Verhoef J, Fluit AC: Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European enterobacteriaceae isolates. Int J Antimicrob Agents 2004, 24(6):585–591.
9. Mshana SE, Kamugisha E, Mirambo M, Chakraborty T, Lyamuya EF: Prevalence of multiresistant gram-negative organisms in a tertiary hospital in Mwanza, Tanzania. BMC Res Notes 2009, 249.
10. Singh N, Patel KM, Leger MM, Short B, Sprague BM, Kalu N, Campos JM: Risk of resistant infections with enterobacteriaceae in hospitalized neonates. Pediatr Infect Dis J 2002, 21(1):1029–1033.
11. Reddy P, Malczynski M, Obiai A, Reiner S, Jin N, Huang J, Noskin GA, Zembower T: Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis 2007, 45(5):846–852.
12. Rodriguez-Bano J, Lopez-Cerero L, Navarro MD, Díaz de Alba P, Pascual A: Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 2008, 62(5):1142–1149.
13. Hawley PM: Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infeet 2008, 14(Suppl 1):159–165.
14. Friedmann R, Raveh D, Zartner E, Rudensky B, Broide E, Attias D, Yinnon AM: Prospective evaluation of colonization with extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing enterobacteriaceae among patients during hospitalization. Infect Control Hosp Epidemiol 2009, 30(6):534–542.
15. Kader AA, Kamath KA: Faecal carriage of extended-spectrum beta-lactamase-producing bacteria in the community. East Meditn Health J 2009, 15(6):1365–1370.
16. Herndrainy P, Randrianirina F, Ratovoson R, Ratsima Hariniana E, Buissin Y, Genel N, Decre D, Arlet G, Talarmin A, Richard V: Rectal carriage of extended-spectrum beta-lactamase-producing gram-negative bacilli in community settings in Madagascar. PLoS One 2011, 6(7):e22738.
17. Tschudin-Sutter S, Frei R, Battegay M, Hoelsl I, Widmer AF: Extended-spectrum β-lactamase-producing escherichia coli in neonatal care unit. Emerg Infect Dis 2010, 16(11):1758–1760.
18. Birgy A, Mairani-Kurkdjian P, Bidet P, Deitl C, Genel N, Couroux C, Arlet G, Bingen E: Characterization of extended-spectrum-beta-lactamase-producing escherichia coli strains involved in maternal-fetal colonization: prevalence of E. coli ST131. J Clin Microbiol 2013, 51(6):1727–1732.
19. Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DS, Urassa WK, Fataki M, Msangi V, Telvekk MG, Mselly SY, Langeland N: High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamas in Dar es Salaam, Tanzania. J Clin Microbiol 2005, 43(2):745–749.
20. Ndugulile F, Jureen R, Harthug S, Urassa W, Langeland N: Extended spectrum beta-lactamas among gram-negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania. BMC Infect Dis 2005, 5:86.
21. Mshana SE, Hain T, Domann E, Lyamuya EF, Chakraborty T, Imraziloglu C: Predominance of Klebsiella pneumoniae ST14 carrying CTX-M-15 causing neonatal sepsis in Tanzania. BMC Infect Dis 2013, 13(4):466.
22. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC: Color Atlas and Textbook of Diagnostic Microbiology. 5th edition. Philadelphia, Pa: Lippincott, Williams & Wilkins Publishers; 1997.
23. CLSI: Performance standards for antimicrobial susceptibility testing: twenty first information supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. vol. CLSI document M100-S21.
24. Stromdahl H, Tham J, Melander E, Walder M, Edquist PJ, Odenholt I: Prevalence of faecal ESBL carriage in the community and in a hospital setting in a county of Southern Sweden. Eur J Clin Microbiol Infect Dis 2011, 30(10):1159–1162.

25. Andriatahina T, Randrianirina F, Hariniana ER, Talarmin A, Raobijaoana H, Buïsson Y, Richard V: High prevalence of faecal carriage of extended-spectrum beta-lactamase-producing escherichia coli and Klebsiella pneumoniae in a pediatric unit in Madagascar. BMC Infect Dis 2010, 10:204.

26. Ofek-Shlomai N, Benenson S, Ergaz Z, Peleg O, Braunstein R, Bar-Oz B: Gastrointestinal colonization with ESBL-producing Klebsiella in preterm babies—is vancomycin to blame? Eur J Clin Microbiol Infect Dis 2012, 31(4):567–570.

27. Tande D, Jallot N, Bougoumoufo F, Montagnon T, Gouriou S, Szun J: Extended-spectrum beta-lactamase-producing enterobacteriaceae in a Malian orphanage. Emerg Infect Dis 2009, 15(3):472–474.

28. Birgy A, Cohen R, Levy C, Bidet P, Courroux C, Benani M, Thollot F, Bingen E: Community faecal carriage of extended-spectrum beta-lactamase-producing enterobacteriaceae in French children. BMC Infect Dis 2012, 12:315.

29. Minami K, Shoji Y, Kasai M, Ogiso Y, Nakamura T, Kawakami Y, Saito Y, Kuzumoto K, Kubota N, Yumoto K, Ishii K: Proportion of rectal carriage of extended-spectrum beta-lactamase-producing enterobacteriaceae in the inpatients of a pediatric tertiary care hospital in Japan. Jpn J Infect Dis 2012, 65(6):548–550.

30. Harris AD, McGregor JC, Johnson JA, Strauss SM, Moore AC, Standiford HC, Hebden JN, Morris JS Jr: Risk factors for colonization with extended-spectrum β-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 2007, 13(8):1144–1149.

doi:10.1186/1756-0500-7-279

Cite this article as: Nelson et al.: Evaluation of existence and transmission of extended spectrum beta lactamase producing bacteria from post-delivery women to neonates at Bugando Medical Center, Mwanza-Tanzania. BMC Research Notes 2014 7:279.